Open access | Opinion

# Unveiling the Promise of Blood-based Biomarkers in Assessing Neurological Complications of COVID-19

**Sophia Olivia**[*]

*Department of Pathology, Evergreen University, United Kingdom*

## INTRODUCTION

The COVID-19 pandemic has not only challenged healthcare systems worldwide but has also revealed the intricate interplay between the virus and various organ systems, including the nervous system. Neurological manifestations of COVID-19, ranging from mild symptoms such as headache and anosmia to severe complications like encephalopathy and stroke, have been increasingly recognized. Amidst the urgency to identify reliable biomarkers for disease prognosis and management, recent advancements in assay platforms have paved the way for the detection of neuronal and glial injury biomarkers in the blood of COVID-19 patients, offering valuable insights into the neurological sequelae of the disease. An FDA-approved assay platform has emerged as a promising tool for detecting biomarkers of neuronal and glial injury in the blood of COVID-19 patients. Leveraging state-of-the-art technology, this platform enables the quantitative measurement of specific biomarkers indicative of neuro-inflammation, neuronal damage, and astrocytic activation. Among the biomarkers of interest are Glial Fibrillary Acidic Protein (GFAP), a marker of astrocytic injury, and neuro-filament light chain (NfL), a marker of neuronal damage, both of which have shown promise in the context of neurological disorders.

## DESCRIPTION

The application of this assay platform in COVID-19 patients has yielded compelling findings regarding the extent and nature of neurological involvement in the disease. Elevated levels of GFAP and NfL have been detected in the blood of COVID-19 patients, particularly those with severe respiratory illness or neurological complications. These findings suggest a link between systemic inflammation, neuroinflammation, and neuronal/glial injury in the context of COVID-19, underscoring the multifaceted nature of the disease process.

Furthermore, the detection of neuronal and glial injury biomarkers in the blood of COVID-19 patients holds significant clinical implications. Firstly, these biomarkers may serve as prognostic indicators, aiding in the early identification of patients at higher risk of developing neurological complications or experiencing disease progression. Secondly, they may facilitate risk stratification and treatment decision-making, guiding the allocation of resources and therapeutic interventions to those most in need. Additionally, longitudinal monitoring of biomarker levels may offer insights into disease trajectory and response to treatment, enabling personalized patient management strategies. Beyond their prognostic and diagnostic utility, blood-based biomarkers of neuronal and glial injury hold promise as surrogate endpoints in clinical trials evaluating novel therapeutics for COVID-19-related neurological complications. By providing objective measures of treatment response and disease progression, these biomarkers may accelerate the development and approval of effective interventions, ultimately improving outcomes for affected individuals. However, challenges remain in the translation of blood-based biomarkers into routine clinical practice.

## CONCLUSION

In conclusion, the advent of an FDA-approved assay platform capable of detecting biomarkers of neuronal and glial injury in the blood of COVID-19 patients represents a significant milestone in our quest to unravel the neurological sequelae of the disease. By providing valuable insights into disease pathophysiology, prognosis, and treatment response, blood-based biomarkers have the potential to revolutionize the management of COVID-19-related neurological complications. As we continue to navigate the complexities of the pandemic, leveraging these biomarkers holds promise for improving patient outcomes and advancing our understanding of COVID-19's impact on the nervous system.